Lepur

Simvastatin, the active ingredient in Lepur, is a HMG‑CoA reductase inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels and reduces cardiovascular risk in adults with hypercholesterolemia or related dyslipidemias. It is indicated for the management of primary dyslipidemia and for secondary prevention of cardiovascular events in patients at elevated risk.

GNH USA supplies Lepur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Simvastatin is used to treat disorders of lipid metabolism and to lower cardiovascular risk.

- Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Primary dyslipidemia: improves overall lipid profile including triglycerides. - Prevention of cardiovascular events: lowers incidence of myocardial infarction and stroke in at‑risk patients.

Simvastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Abdominal pain: discomfort in the stomach area, may be intermittent. - Nausea: feeling of sickness, sometimes accompanied by vomiting. - Myalgia: muscle aches without weakness, usually localized. - Constipation: difficulty passing stools, may require dietary adjustment. - Dyspepsia: indigestion or heartburn, often relieved by antacids.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury, requires immediate medical attention. - Hepatic dysfunction: elevated liver enzymes or hepatitis, monitored through liver function tests. - Severe allergic reactions: rash, swelling, or anaphylaxis, may need emergency treatment. - Elevated transaminases: significant increase in ALT/AST levels, indicating liver stress. - Myopathy: muscle weakness with elevated creatine kinase, may progress if untreated. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain and elevated enzymes.

Before initiating Simvastatin therapy, several safety considerations should be reviewed.

- Liver function monitoring: obtain baseline hepatic enzymes and repeat periodically. - Drug interaction review: assess concomitant medications that affect CYP3A4 metabolism. - Renal function assessment: evaluate kidney status in patients with chronic renal disease. - Avoid grapefruit products: grapefruit juice can increase simvastatin plasma concentrations. - Use caution in elderly: increased susceptibility to myopathy and drug interactions. - Pregnancy and breastfeeding: safety not established; avoid use unless benefits outweigh risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Simvastatin interacts with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors): can markedly raise simvastatin levels. - Gemfibrozil: combined use significantly increases risk of myopathy and rhabdomyolysis. - Cyclosporine: elevates simvastatin concentrations, heightening muscle toxicity. - High‑dose niacin: may potentiate muscle adverse effects.

Moderate Interactions (Monitor Closely): - Amiodarone: may increase simvastatin exposure modestly. - Warfarin: concurrent use can alter anticoagulant effect, requiring INR monitoring. - Digoxin: potential for increased serum levels, monitor for toxicity. - Erythromycin: moderate CYP3A4 inhibition, may raise simvastatin levels. - Grapefruit juice: can increase drug exposure, advise limited consumption.